EdgarLookup

Hypha Labs, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Hypha Labs, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-163.4%
Profit Margin
Net income ÷ revenue
-758%
Return on Assets
Net income ÷ assets
-1.03x
Debt-to-Equity
Total liabilities ÷ equity
+131.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2017 Sep 30, 2017 $1.90M Dec 29, 2017
FY2017 Sep 30, 2016 $818.6K Dec 29, 2017
FY2016 Sep 30, 2015 $16.1K Jan 9, 2017
FY2015 Sep 30, 2014 $54.9K Jan 13, 2016
FY2014 Sep 30, 2013 $567.2K Nov 25, 2014

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2022 Sep 30, 2022 $2.70M Jan 17, 2023
FY2022 Sep 30, 2021 $2.50M Jan 17, 2023
FY2021 Sep 30, 2020 $2.57M Dec 29, 2021
FY2020 Sep 30, 2019 $2.55M Jan 29, 2021
FY2019 Sep 30, 2018 $2.84M Dec 31, 2019
FY2018 Sep 30, 2017 $1.90M Dec 27, 2018

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2013 Sep 30, 2013 $567.2K Dec 30, 2013
FY2013 Sep 30, 2012 $391.7K Dec 30, 2013
FY2011 Sep 30, 2011 $95.9K Dec 29, 2011

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2022 Sep 30, 2022 $1.07M Jan 17, 2023
FY2022 Sep 30, 2021 $715.2K Jan 17, 2023
FY2021 Sep 30, 2020 $795.8K Dec 29, 2021
FY2020 Sep 30, 2019 $839.8K Jan 29, 2021
FY2019 Sep 30, 2018 $770.1K Dec 31, 2019
FY2018 Sep 30, 2017 $994.0K Dec 27, 2018
FY2017 Sep 30, 2016 $438.5K Dec 29, 2017
FY2016 Sep 30, 2015 ($69.5K) Jan 9, 2017
FY2015 Sep 30, 2014 $25.7K Jan 13, 2016
FY2014 Sep 30, 2013 $263.2K Nov 25, 2014

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 ($3.10M) Jan 15, 2026
FY2025 Sep 30, 2024 ($785.4K) Jan 15, 2026
FY2024 Sep 30, 2023 $246.8K Jan 13, 2025
FY2023 Sep 30, 2022 ($2.06M) Jan 19, 2024
FY2022 Sep 30, 2021 ($686.5K) Jan 17, 2023
FY2021 Sep 30, 2020 ($2.31M) Dec 29, 2021
FY2020 Sep 30, 2019 ($1.81M) Jan 29, 2021
FY2019 Sep 30, 2018 ($1.65M) Dec 31, 2019
FY2018 Sep 30, 2017 ($1.07M) Dec 27, 2018
FY2017 Sep 30, 2016 ($3.70M) Dec 29, 2017

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 ($3.00M) Jan 15, 2026
FY2025 Sep 30, 2024 ($1.83M) Jan 15, 2026
FY2024 Sep 30, 2023 ($437.4K) Jan 13, 2025
FY2023 Sep 30, 2022 ($1.15M) Jan 19, 2024
FY2022 Sep 30, 2021 ($772.4K) Jan 17, 2023
FY2021 Sep 30, 2020 ($2.19M) Dec 29, 2021
FY2020 Sep 30, 2019 ($1.84M) Jan 29, 2021
FY2019 Sep 30, 2018 ($1.76M) Dec 31, 2019
FY2018 Sep 30, 2017 ($1.30M) Dec 27, 2018
FY2017 Sep 30, 2016 ($2.88M) Dec 29, 2017

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2015 Sep 30, 2015 $143.8K Jan 13, 2016
FY2015 Sep 30, 2014 $23.1K Jan 13, 2016

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 ($380.0K) Jan 15, 2026
FY2025 Sep 30, 2024 ($1.03M) Jan 15, 2026
FY2024 Sep 30, 2023 $112.5K Jan 13, 2025
FY2023 Sep 30, 2022 ($184.8K) Jan 19, 2024
FY2022 Sep 30, 2021 ($136.0K) Jan 17, 2023
FY2021 Sep 30, 2020 ($671.6K) Dec 29, 2021
FY2020 Sep 30, 2019 ($1.04M) Jan 29, 2021
FY2019 Sep 30, 2018 ($163.4K) Dec 31, 2019
FY2018 Sep 30, 2017 ($376.9K) Dec 27, 2018
FY2017 Sep 30, 2016 ($734.1K) Dec 29, 2017

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $33.0K Jan 15, 2026
FY2025 Sep 30, 2024 $27.7K Jan 15, 2026
FY2022 Sep 30, 2022 $17.7K Jan 17, 2023
FY2022 Sep 30, 2021 $56.2K Jan 17, 2023
FY2021 Sep 30, 2020 $141.2K Dec 29, 2021
FY2020 Sep 30, 2019 $45.1K Jan 29, 2021
FY2019 Sep 30, 2018 $207.4K Dec 31, 2019
FY2018 Sep 30, 2017 $140.8K Dec 27, 2018
FY2017 Sep 30, 2016 $13.8K Dec 29, 2017
FY2016 Sep 30, 2015 $1.44M Jan 9, 2017

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $409.2K Jan 15, 2026
FY2025 Sep 30, 2024 $493.8K Jan 15, 2026
FY2024 Sep 30, 2023 $1.41M Jan 13, 2025
FY2023 Sep 30, 2022 $1.34M Jan 19, 2024
FY2022 Sep 30, 2021 $1.89M Jan 17, 2023
FY2021 Sep 30, 2020 $1.79M Dec 29, 2021
FY2020 Sep 30, 2019 $1.36M Jan 29, 2021
FY2019 Sep 30, 2018 $1.40M Dec 31, 2019
FY2018 Sep 30, 2017 $1.57M Dec 27, 2018
FY2017 Sep 30, 2016 $1.45M Dec 29, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 $2.51M Jan 15, 2026
FY2025 Sep 30, 2024 $1.42M Jan 15, 2026
FY2024 Sep 30, 2023 $3.28M Jan 13, 2025
FY2023 Sep 30, 2022 $3.75M Jan 19, 2024
FY2022 Sep 30, 2021 $2.94M Jan 17, 2023
FY2021 Sep 30, 2020 $2.88M Dec 29, 2021
FY2020 Sep 30, 2019 $930.1K Jan 29, 2021
FY2019 Sep 30, 2018 $384.6K Dec 31, 2019
FY2018 Sep 30, 2017 $164.0K Dec 27, 2018
FY2017 Sep 30, 2016 $211.9K Dec 29, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 ($2.44M) Jan 15, 2026
FY2025 Sep 30, 2024 ($1.26M) Jan 15, 2026
FY2025 Sep 30, 2023 ($2.21M) Jan 15, 2026
FY2024 Sep 30, 2022 ($2.74M) Jan 13, 2025
FY2023 Sep 30, 2021 ($1.05M) Jan 19, 2024
FY2022 Sep 30, 2020 ($1.09M) Jan 17, 2023
FY2021 Sep 30, 2019 $425.9K Dec 29, 2021
FY2020 Sep 30, 2018 $1.01M Jan 29, 2021
FY2019 Sep 30, 2017 $1.41M Dec 31, 2019
FY2018 Sep 30, 2016 $1.23M Dec 27, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2021 Sep 30, 2020 $592.6K Dec 29, 2021

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 ($23.65M) Jan 15, 2026
FY2025 Sep 30, 2024 ($20.55M) Jan 15, 2026
FY2024 Sep 30, 2023 ($19.76M) Jan 13, 2025
FY2023 Sep 30, 2022 ($20.01M) Jan 19, 2024
FY2022 Sep 30, 2021 ($17.95M) Jan 17, 2023
FY2021 Sep 30, 2020 ($17.27M) Dec 29, 2021
FY2020 Sep 30, 2019 ($14.96M) Jan 29, 2021
FY2019 Sep 30, 2018 ($13.15M) Dec 31, 2019
FY2018 Sep 30, 2017 ($11.50M) Dec 27, 2018
FY2017 Sep 30, 2016 ($10.43M) Dec 29, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2022 Sep 30, 2022 $56.2K Jan 17, 2023
FY2022 Sep 30, 2021 $295.9K Jan 17, 2023
FY2021 Sep 30, 2020 $82.7K Dec 29, 2021
FY2020 Sep 30, 2019 $323.7K Jan 29, 2021
FY2019 Sep 30, 2018 $176.0K Dec 31, 2019
FY2018 Sep 30, 2017 $178.2K Dec 27, 2018
FY2018 Sep 30, 2016 $135.4K Dec 27, 2018
FY2017 Sep 30, 2015 $481.1K Dec 29, 2017
FY2016 Sep 30, 2014 $5.10M Jan 9, 2017
FY2015 Sep 30, 2013 $35.4K Jan 13, 2016

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 0 Jan 15, 2026
FY2025 Sep 30, 2024 0 Jan 15, 2026
FY2024 Sep 30, 2023 0 Jan 13, 2025
FY2023 Sep 30, 2022 0 Jan 19, 2024
FY2022 Sep 30, 2021 0 Jan 17, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 0 Jan 15, 2026
FY2025 Sep 30, 2024 0 Jan 15, 2026
FY2024 Sep 30, 2023 0 Jan 13, 2025
FY2023 Sep 30, 2022 0 Jan 19, 2024

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Sep 30, 2025 147.12M Jan 15, 2026
FY2025 Sep 30, 2024 123.05M Jan 15, 2026
FY2024 Sep 30, 2023 87.10M Jan 13, 2025
FY2023 Sep 30, 2022 75.15M Jan 19, 2024
FY2022 Sep 30, 2021 71.23M Jan 17, 2023
FY2021 Sep 30, 2020 58.27M Dec 29, 2021
FY2020 Sep 30, 2019 48.36M Jan 29, 2021
FY2019 Sep 30, 2018 42.25M Dec 31, 2019
FY2018 Sep 30, 2017 35.03M Dec 27, 2018
FY2017 Sep 30, 2016 22.49M Dec 29, 2017